Skip to main content
. Author manuscript; available in PMC: 2020 Dec 21.
Published in final edited form as: Urol Oncol. 2019 Aug 6;37(10):688–695. doi: 10.1016/j.urolonc.2019.05.017

Table 2B,

Incremental Cost Effectiveness Ratios – Base Case and Alternate Scenarios

ICER
DCT vs ADT DCT vs AA
Main Model (PF-QALYs) $50,489 $1,009,975
No QALY adjustment (PF-LYs) $44,368 $969,532
Model VA price (PF-QALYs) $50,489 $575,031
Model with 1/4 dose (PF-QALYs) $50,489 $208,062